Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.96 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Juvenile Investing Mob
Tech stocks did well in Europe but not in the US. The data are unconvincing. 
Via Talk Markets
FDA surprise
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
Exposures Product Safety
Safety Concerns, Lower Demand Interrupts Use of Johnson & Johnson COVID-19 Shot: Reuters
Amid safety concerns about Johnson & Johnson’s (NYSE: JNJ) COVID-19 vaccine, along with the weakening of demand for vaccinations, around half of 21 million... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
Does AstraZeneca's COVID Vaccine Have a Future?
Yes, but it could be a bumpy one. 
Via The Motley Fool
Exposures COVID-19
Will Mixing Different COVID Vaccines Be Likely Down the Road?
Maybe, but maybe not. 
Via The Motley Fool
Exposures COVID-19
A Better Switch
Today the US market decided to rise because President Biden is pondering not linking his infrastructure project to a corporate tax increase. 
Via Talk Markets
AstraZeneca Unveils 5-Year Survival Data for Imfinzi in Lung Cancer Patients
AstraZeneca Plc’s (NASDAQ: AZN) has announced updated results from the PACIFIC Phase 3 trial of Imfinzi (durvalumab), showing survival benefit at five years... 
Via Benzinga
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... 
Via Benzinga
AstraZeneca, Merck Lynparza Earns Win in Early Breast Cancer, Showing Potential in Post-Surgery Setting
AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating... 
Via Benzinga
Fan Hit
The 10-yr US treasury yield rose to 1.6% again. Later in the day, a rally was attempted, mostly for the meme shares. 
Via Talk Markets
Valneva Concludes Recruitment for COVID-19 Vaccine Candidate Trial
Privately-held Valneva SE has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001... 
Via Benzinga
Exposures COVID-19
AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (... 
Via Benzinga
Exposures COVID-19
Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or... 
Via Benzinga
AstraZeneca, Proteros Team Up To Develop Novel Anti-Cancer Medicines
Privately-held Proteros biostructures GmbH has signed an agreement with AstraZeneca Plc (NASDAQ: AZN) to jointly discover and develop novel small... 
Via Benzinga
AstraZeneca's Anifrolumab Shows Benefit In Skin, Joint Diseases In Systemic Lupus Erythematosus Patients
AstraZeneca Plc (NASDAQ: AZN) has announced a new posthoc analysis of pooled data from the TULIP Phase 3 clinical trials evaluating anifrolumab in patients with... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
Exposures Product Safety
CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed
CureVac BV (NASDAQ: CVAC) said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data.... 
Via Benzinga
Exposures COVID-19
2 Deeply Discounted Dividend Stocks to Buy and Hold Right Now
These pharmaceutical companies might make great long-term additions to your portfolio. 
Via The Motley Fool
More Inflationary Pressures
Today, we saw more evidence of worrying inflationary pressures from the personal consumption index hitting 3.1% in April over prior April, up sharply from the March rise of 1.9%. 
Via Talk Markets
Emergent BioSolutions Poised To Receive FDA Nod to Restart J&J COVID-19 Shot Production at Baltimore Plant After Mishap: WSJ
The FDA and Johnson & Johnson (NYSE: JNJ) are expected to announce that contamination problems at Emergent BioSolutions Inc’s (NYSE: EBS) Baltimore... 
Via Benzinga
Exposures COVID-19 Product Safety
AstraZeneca's Tagrisso Wins European Approval In Early Lung Cancer
AstraZeneca Plc’s (NASDAQ: AZN) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung... 
Via Benzinga
Is It Too Late to Buy the Most Promising Pipeline in the Pharma Industry?
Fast-growing AstraZeneca might make an interesting addition to your portfolio. 
Via The Motley Fool
COVID Vaccine Update: Where J&J, AstraZeneca, Novavax, and Sinovac Stand Now
Several of these vaccine makers face challenges. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
India To Skip Local Trials for 'Well Established' COVID-19 Vaccines; Pfizer Shots May Arrive By July: Reuters
As a step to accelerate vaccination rollout, India has reportedly scrapped local trials for “well-established” foreign COVID-19 vaccines, with a government... 
Via Benzinga
Exposures COVID-19
Good Times For Gold
Gold is rising some more, in part as an alternative to crypto. 
Via Talk Markets
EU Seeks Fines For AstraZeneca Over COVID-19 Vaccine Delays: Reuters
The European Union took on AstraZeneca Plc (NASDAQ: AZN) in a Brussels court and accused it of diverting doses promised to the bloc to other nations. EU’s... 
Via Benzinga
Exposures COVID-19
FDA May Not Review New COVID-19 Vaccine Emergency Use Requests
The FDA, on Tuesday, said that it might decline to review and process new emergency use authorization (EUA) requests for COVID-19 vaccines for the rest of the pandemic... 
Via Benzinga
Exposures COVID-19 Product Safety
Nipro To Provide Fill, Finish Services For AstraZeneca COVID-19 Shots In Japan: Reuters
Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro... 
Via Benzinga
Exposures COVID-19
Sterling At Five-Year High
Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. 
Via Talk Markets
< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.